New to GLP-1s? Start with whether it's right for you ->
Brand Ozempic vs compounded semaglutide cost: the short answer
On cost, it is not close: brand Ozempic runs roughly $1,000-1,350/mo cash list without insurance (and around $400/mo even when partially discounted), while compounded semaglutide from a 503A pharmacy lands around $150-220/mo. But cost is only half the brand-Ozempic-vs-compounded-semaglutide decision - the other half is access and regulation. Brand Ozempic is FDA-approved, manufactured by Novo Nordisk, and if your insurance covers it your real out-of-pocket can drop below the cash price of compounded. Compounded semaglutide is legal only under the FDA 503A shortage framework, is not FDA-approved, and that access can narrow if the shortage is declared resolved. So the honest answer: compounded is far cheaper today, brand is the higher-oversight option and can be cheaper than it looks with insurance, and the right call depends on your coverage and your tolerance for the shortage-framework risk. A real provider consult should price both before defaulting you to either.
What the numbers actually look like
Here is brand versus compounded laid out on both axes that actually matter - the monthly cost and the regulatory category that comes with it. Same active molecule (semaglutide), very different price and oversight.
| Pricing scenario | Per month | Why |
|---|---|---|
| Brand cash list (Ozempic/Wegovy) | $1,000-1,350/mo | US manufacturer list price before coupons or savings cards - FDA-approved, Novo Nordisk |
| Brand, partial discount / no insurance | ~$400/mo | VOC anchor: the 'way more than I can afford' real number a buyer hit without coverage |
| Brand with insurance coverage | copay varies | If covered, your out-of-pocket can fall well below cash compounded - the path a real consult surfaces first |
| Compounded semaglutide, all-in | $158-217/mo | TMates transparent dose-tier pricing, 503A pharmacy, FDA shortage framework, not FDA-approved |
| Compounded, bought quarterly | ~$150/mo | Real r/SemaglutideCompound buyer: $1,800 up front for 12 months via HERS |
Bottom line: Compounded is the cheaper path today by a wide margin. But check your insurance for brand coverage first - if it is covered, brand can be cheaper than compounded and carries full FDA oversight. And remember compounded access is contingent on the shortage framework holding.
Sources: partner pricing captured directly from provider sites; veteran and brand anchors from cited Reddit threads and US manufacturer list prices. We do not invent numbers - every figure traces to a named source.
What actually drives the price
- Regulatory category. Brand Ozempic and Wegovy are FDA-approved drugs with full manufacturing oversight. Compounded semaglutide is made by a 503A pharmacy under the FDA shortage framework - legal while the shortage holds, but not FDA-approved and not subject to the same review. That difference is the whole reason the prices diverge.
- Insurance changes the math. The brand cash list looks brutal, but if your plan covers Wegovy or Ozempic your copay can land well below the cash price of compounded. A real provider consult should check this before defaulting you to compounded - skipping that check is exactly the conflict-of-interest gap our framework scores.
- Shortage-framework risk. Compounded semaglutide is legal only while semaglutide is on the FDA shortage list. If the shortage is declared resolved, compounding pharmacies generally have to stop making it, and the cheap path can narrow. If long-term access matters, factor that risk in rather than betting everything on the shortage holding.
- Salt-form caution on the cheap end. Some vendors sell semaglutide sodium (a salt-form variation) marketed as bioequivalent to the FDA-approved active. It is not, and marketing it that way is a categorical disqualifier in our framework. If a compounded quote is unusually cheap, confirm the active is base semaglutide from a named 503A pharmacy, not the salt.
Where to get it
Honest take on where to source this peptide. Open the free account first; that's how we get credited even if you skip the code at checkout.
Transparent-pricing telehealth marketplace ยท Katalys
Sesame Care
Fits: You want a real video consult with a US-licensed provider who surfaces the brand-name + insurance pathway honestly alongside cash-pay compounded - not an async rubber-stamp. Composite 34.5/50, the highest of the audited cohort (Tier B verging on A).
Watch: Marketplace model: the experience varies by which provider you book, and 5 of 10 doctor-ethical axes are still pending our sign-up walkthrough. We score what we can verify and flag what we cannot. Read provider reviews before booking.
Step 1 Open a free account at Sesame Care ->Affiliate relationships are disclosed per FTC rules. Editorial take is independent of any commercial relationship; we only recommend what we'd actually use.
Questions readers actually ask
Is brand Ozempic worth the extra cost over compounded semaglutide?
It depends entirely on your insurance. At cash list (~$1,000-1,350/mo) brand Ozempic is hard to justify over compounded semaglutide at ~$150-220/mo for most people. But if your plan covers Ozempic or Wegovy, your copay can fall below the cash price of compounded - at which point brand is both cheaper for you and carries full FDA oversight. Check your coverage before assuming compounded is the only affordable path; a real provider consult will surface the insurance route first.
Can a telehealth provider prescribe brand Ozempic, or only compounded?
A real provider can prescribe either. The difference is the platform: a single-product compounded-GLP-1 funnel is structurally pointed at compounded, while a doctor-first marketplace like Sesame Care lets the booked provider write brand-name Ozempic, Wegovy, or Zepbound and route it through your insurance, or evaluate compounded if that fits better. That is why our framework scores the doctor-first model higher on conflict-of-interest disclosure - it is not incentivized to default everyone to one SKU.
What happens to compounded semaglutide access when the FDA shortage ends?
Compounded semaglutide is legal under the FDA 503A shortage framework only while semaglutide is on the shortage list. If the FDA declares the shortage resolved, compounding pharmacies generally must stop producing it, and the inexpensive compounded path can narrow or close. That is the real risk to plan around: if long-term, predictable access matters to you, a path that also establishes the brand-name and insurance route is safer than betting on the shortage holding indefinitely.
Is brand Ozempic the same drug as compounded semaglutide?
The active molecule is semaglutide in both, but they are not the same product or the same regulatory category. Brand Ozempic is the FDA-approved, Novo-Nordisk-manufactured version with full oversight on potency, purity, and sterility. Compounded semaglutide is mixed by a 503A pharmacy under the FDA shortage framework and is not FDA-approved. For most people the practical decision is cost versus oversight: compounded is far cheaper today, brand carries the full approval and may be cheaper than its list price if your insurance covers it.
Should I switch from brand Ozempic to compounded semaglutide to save money?
Maybe, but check your insurance first. If your plan covers brand Ozempic or Wegovy, your copay could already be lower than cash-pay compounded - in which case switching costs you both money and FDA oversight. If you are paying the brand cash price (~$1,000-1,350/mo) or the partial-discount ~$400/mo, compounded at ~$150-220/mo is a large saving, but you take on the not-FDA-approved status and the shortage-framework access risk. A real provider consult that prices both paths is the right way to decide rather than switching blind.
Where to go next
- Compounded vs branded GLP-1 - the fuller regulatory and quality breakdown
- Compounded semaglutide vs Wegovy - the direct molecule-by-molecule comparison
- The full GLP-1 telehealth matrix - all the audited partners side by side
- How we evaluate partners - the 10-axis framework and the public audit log
- Should you get on a GLP-1? - the decision before the provider
- Subscribe to the dispatch
Subscribe to the dispatch
None of this replaces a doctor. Compounded GLP-1s are dispensed under the FDA 503A shortage framework, not FDA-approved. Pricing changes. Talk to a real prescriber before you start, switch, or stop anything.